An EMA ITF Briefing Meeting with RESCEU representatives took place on March 16th at the EMA headquarters, as part of the RESCEU efforts for establishing continuous communication and collaboration with Regulatory Bodies.
The purpose of this collaboration is to allow RESCEU to receive fundamental regulatory input but also provide, thanks to its experts and the data generated within the project, a useful and valid scientific support to EMA for all those matters related to the development of medicinal products intended for the treatment and prophylaxis of RSV infection. The meeting started with the presentation of RESCEU, its structure and objectives for the next 4 years, and was followed by a discussion where RESCEU Leads sought advice on ways for communicating with EMA and clinically related topics, such as information that should be captured by the clinical studies in view of future regulatory discussion.